High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia.
OBJECTIVE
Benign prostatic hyperplasia is common among men who may be candidates for prostate cancer screening using prostate-specific antigen (PSA) testing. Patterns of PSA testing among men with evidence of benign prostatic hyperplasia have not been studied.


METHODS
We examined the prevalence and correlates of a self-reported history of PSA testing. In 1994, 33,028 US health professionals without prostate cancer aged 47 to 85 years provided information on prior PSA testing, lower urinary tract symptoms characteristic of benign prostatic hyperplasia, history of prostatectomy, and prostate cancer risk factors. In 1995, a subset of 7,070 men provided additional information on diagnosis and treatment of benign prostatic hyperplasia.


RESULTS
From 39% of men in their 50s to 53% of men in their 80s reported PSA testing in the prior year (P <0.0001 for trend with age). Men were more likely to report PSA testing if they had lower urinary tract symptoms characteristic of benign prostatic hyperplasia (age-adjusted odds ratio for severe symptoms 2.2, 95% confidence interval 1.8 to 2.6), a prior history of prostatectomy (age-adjusted odds ratio 1.1, 95% confidence interval 1.02 to 1.2), or a physician diagnosis of benign prostatic hyperplasia (odds ratio 1.9, 95% confidence interval 1.7 to 2.2; adjusted for age, signs or symptoms of benign prostatic hyperplasia, and prostate cancer risk factors).


CONCLUSIONS
These US health professionals reported preferential use of PSA testing among men least likely to benefit from early cancer detection (older men) and among men most likely to have a false-positive PSA result (men with benign prostatic hyperplasia). Physician and patient education are needed to promote more rational and selective use of this screening test.
Meigs
J B
JB
Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston 02114, USA.
Barry
M J
MJ
Giovannucci
E
E
Rimm
E B
EB
Stampfer
M J
MJ
Kawachi
I
I
D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D007118:Immunoassay / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D015166:Monitoring, Immunologic / Q000706:statistics & numerical data*; D016017:Odds Ratio; D015995:Prevalence; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000517:prevention & control*; D012307:Risk Factors; D014481:United States
D017430:Prostate-Specific Antigen